- Home
- INCY vs ESS Comparison
INCY vs ESS Comparison
Compare INCY & ESS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- ESS
- Stock Information
- Founded
- INCY 1991
- ESS 1971
- Country
- INCY United States
- ESS United States
- Employees
- INCY N/A
- ESS N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- ESS Real Estate Investment Trusts
- Sector
- INCY Health Care
- ESS Real Estate
- Exchange
- INCY Nasdaq
- ESS Nasdaq
- Market Cap
- INCY 17.0B
- ESS 16.6B
- IPO Year
- INCY 1993
- ESS 1994
- Fundamental
- Price
- INCY $91.48
- ESS $265.19
- Analyst Decision
- INCY Buy
- ESS Hold
- Analyst Count
- INCY 19
- ESS 18
- Target Price
- INCY $81.73
- ESS $298.21
- AVG Volume (30 Days)
- INCY 1.7M
- ESS 414.3K
- Earning Date
- INCY 10-28-2025
- ESS 10-29-2025
- Dividend Yield
- INCY N/A
- ESS 3.88%
- EPS Growth
- INCY 900.04
- ESS 54.17
- EPS
- INCY 4.37
- ESS 12.44
- Revenue
- INCY $4,584,996,000.00
- ESS $1,887,957,000.00
- Revenue This Year
- INCY $16.41
- ESS $4.02
- Revenue Next Year
- INCY $10.86
- ESS $3.80
- P/E Ratio
- INCY $20.90
- ESS $21.27
- Revenue Growth
- INCY 18.87
- ESS 9.79
- 52 Week Low
- INCY $53.56
- ESS $243.85
- 52 Week High
- INCY $92.86
- ESS $316.29
- Technical
- Relative Strength Index (RSI)
- INCY 67.77
- ESS 55.25
- Support Level
- INCY $84.38
- ESS $260.61
- Resistance Level
- INCY $92.86
- ESS $266.58
- Average True Range (ATR)
- INCY 2.44
- ESS 4.20
- MACD
- INCY 0.35
- ESS 0.76
- Stochastic Oscillator
- INCY 86.26
- ESS 88.57
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 258 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.